Guardant Health Reports Strong Q2 2026 Performance and Raises Full-Year Revenue Guidance
Guardant Health reported strong second-quarter results for fiscal year 2026 with a 44% year-over-year revenue increase driven by growth across its Oncology, Biopharma, and Screening segments. The company attributed the success to increased adoption of its 'Smart Platform' and Reveal product line, which saw over 100% quarterly growth for the third consecutive quarter. Management highlighted the clinical advantages of integrating genomic and epigenomic data in oncology testing. The Screening business also performed well due to a productivity boost from Quest collaboration and direct-to-consumer marketing efforts. Guardant raised its full-year revenue guidance to $1.34 billion - $1.36 billion, citing stronger-than-expected demand across segments. The company expects operational efficiencies following the transition of its liquid biopsy test to the NovaSeq X platform. Guardant also announced key strategic milestones including FDA approval for Guardant360 Liquid CDx and plans to seek ADLT designation in 2027, which could significantly increase Medicare reimbursement rates.
Topics: guidance_update oncology operational_efficiency revenue_growth screening_business